Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response

The introduction of Janus kinase (JAK) 1/2 inhibitor ruxolitinib into the armamentarium of myelofibrosis therapies has allowed to effectively control systemic symptoms, reduce splenomegaly, and imp...